Table 1

Characteristics of Patients Who Underwent Pulmonary Vein Isolation for Paroxysmal or Persistent Atrial Fibrillation

New-NPVF (−) Group (n = 162)New-NPVF (+) Group (n = 54)p Value
Female/male34/12815/39NS
Age (yrs)61.5 ± 12.063.1 ± 14.1NS
Persistent AF37 (23.0)7 (13.0)NS
AF history (months)33.2 ± 50.263.1 ± 81.20.013
CHADS2 score1.1 ± 1.21.2 ± 1.3NS
Congestive heart failure20 (12.3)6 (11.1)NS
Hypertension75 (46.3)21 (38.9)NS
Diabetes24 (15.4)7 (13.0)NS
Stroke17 (10.5)10 (18.5)NS
Body mass index (kg/m2)24.2 ± 3.623.8 ± 3.2NS
Apnea hypopnea index (events/h)10.0 ± 12.28.5 ± 9.7NS
Organic heart disease29 (17.9)12 (22.2)NS
Ejection fraction (%)64.1 ± 11.363.7 ± 9.7NS
LA diameter (mm)39.8 ± 19.138.1 ± 6.2NS
E/e10.4 ± 5.410.0 ± 4.2NS
LA volume (ml)120.0 ± 38.4117.2 ± 36.5NS
LA-PV reconnection116 (71.6)45 (83.3)NS
Number of reconnected PVs1.4 ± 1.21.6 ± 1.2NS
Uncommon atrial flutter12 (7.4)5 (9.2)NS
AF substrate ablation7 (4.3)2 (3.7)NS
Cavo-tricuspid isthmus ablation40 (24.7)11 (20.4)NS
Follow-up period after second session (days)737.5 ± 299.6848.5 ± 390.8NS

Values are n, mean ± SD, or n (%). The study population was divided into groups according to whether or not NPVF developed between the first and second sessions of PV isolation: new-NPVF(+) versus new-NPVF(−). LA volume was estimated via computed tomography.

AF = atrial fibrillation; LA = left atrial; NPVF = nonpulmonary vein foci; NS = not significant; PV = pulmonary vein.